¡Ya estamos en ! Descubre más

KAPA

Kairos Pharma

KAPA

Capitalización de mercado USD 2.04 M

0.6013 USD

-0.0693

10.33%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

0.6106

+0.0093

1.55%

1 día

-10.33%

5 días

-26.18%

1 mes

-66.78%

3 meses

-74.74%

6 meses

-85.95%

En lo que va del año

-88.23%

1 año

-92.66%

5 años

-96.7%

10 años

-96.7%

Acerca de: Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.

Empleados: 1

Atención médica Fabricantes de medicamentos - General

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 100%

Negativo 0%

Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

Kairos Pharma Ltd. (NYSE:KAPA) on Tuesday announced interim efficacy results from its ongoing Phase 2 clinical trial testing ENV-105 alongside apalutamide for patients with metastatic castration-resistant prostate cancer.

Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all.

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference's website. Bhow.

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)---- $KAPA #HCW--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Presentation Date: September 14, 2026 Time: 4:00 PM Eastern Time (Holmes 1) Webcast Link:.

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kairos Pharma Announces 1-for-7 Reverse Stock Split

LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a spl.

Kairos Pharma Announces 1-for-7 Reverse Stock Split

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer

LOS ANGELES--(BUSINESS WIRE)---- $KAPA #Bayer--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma's lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Kairos Pharma's current programs with.

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer

CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever

Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers. Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc. , is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality.

CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced compelling interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca's Tagrisso®) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The data represent a pivotal milestone in Kairos Pharma's lead program: resensitizing patien.

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

Zacks Investment Research

All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy

Kairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy

Kapa Gold Announces the Results of Its 2026 Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - June 19, 2026) - KAPA GOLD INC. (TSXV: KAPA) ("Kapa" or the "Company") is pleased to announce the results of its annual meeting of shareholders held virtually online on June 18, 2026 (the "Meeting").

Kapa Gold Announces the Results of Its 2026 Annual General Meeting

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™